Developer docs
API playgroundTry for free, no card

Search company profiles

Combinostics

Full company profile

uuid0002oka

Namestring
Combinostics
Legal namestring
Combinostics Oy
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Combinostics Oy (founded 2014, headquartered in Tampere, Finland, with a US subsidiary, Combinostics US Inc., in Boston) develops AI-driven neuroimaging diagnostic software for neurodegenerative diseases. Its core offering is the cloud-based cNeuro platform, which combines two integrated applications: cMRI, which performs fully automated quantification of brain MRI scans (detecting atrophy, white-matter abnormalities, and benchmarking against reference data); and cDSI (Clinical Decision Support), which uses a patented disease-state-fingerprint machine-learning method to compare a patient's imaging biomarkers against more than 2,000 confirmed cases of Alzheimer's disease, frontotemporal dementia, vascular dementia, and cognitively normal patients to support differential diagnosis and predict disease progression. The platform also includes cPET for PET image quantification and cDAT for DAT SPECT quantification (released in Europe in December 2023). Marketing materials position Combinostics as the only vendor offering a complete AI solution spanning the full patient-care pathway for major neurological disorders, integrating imaging biomarkers with clinical, neuropsychological, and demographic data.

The company sells cNeuro primarily through enterprise field sales to memory clinics, neurology departments, radiology departments, and nuclear-medicine units within hospitals and healthcare systems (named reference customers include Karolinska University Hospital, CIMF Fribourg, and Unilabs Sweden), supplemented by strategic technology integrations with GE Healthcare, Siemens Healthineers, and Sectra that distribute the platform through major imaging-vendor installed bases. Revenue is generated via cloud-based recurring subscription, with separate US and EU regional cloud portals for data-hosting compliance. The company remained privately held and small-scale (11-50 employees) until January 2, 2025, when it was acquired by SyntheticMR AB for EUR 4.3 million (~$5.03 million), mostly in cash with the remainder via promissory note and convertibles, and now operates as a wholly-owned subsidiary within SyntheticMR's AI-based neuroimaging portfolio.

Combinostics participates in industry conferences (notably RSNA), maintains thought-leadership content on neuroimaging and AI, and operates a free-trial and demo-request funnel. The company's addressable market — AI-assisted brain diagnostics — is projected to grow from $1.74 billion in 2024 to $5.46 billion in 2029, with the broader brain AI-assisted diagnosis market forecasted at $6.84 billion by 2030 at a 25.5% CAGR. Independent revenue figures are not publicly disclosed; the modest acquisition valuation relative to a high-growth end market implies sub-$5M standalone ARR on the eve of the SyntheticMR transaction.

Short descriptiontext

Combinostics is a Finland-based medical technology company that provides AI-powered neuroimaging diagnostic support for neurodegenerative diseases via its cloud-based cNeuro platform, sold to hospitals, memory clinics, and radiology/nuclear-medicine departments across Europe and the US.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTampere, Finland
HQ citystring
Tampere
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuroimaging software, AI diagnostic platform, brain MRI quantification, neurodegenerative disease diagnostics, clinical decision support
Industry4 codes
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code2 codes
  • Computer Systems Design and Related Services54151
  • Other Computer Related Services541519
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging AI Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1cNeuro Platform Subscription
TypeSubscription Recurring
Description

Cloud-based AI diagnostic platform offered as subscription service to healthcare providers, hospitals, and medical imaging centers for neuroimaging analysis and neurodegenerative disease diagnosis support.

combinostics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1cNeuro
Description

A complete cloud-based AI solution for early detection, diagnosis, and management of major neurological disorders. Combines cMRI and cDSI applications.

combinostics.com
+4 more records
Core offering1 text field

Combinostics develops and sells the cloud-based cNeuro platform, an AI-driven diagnostic suite for the early detection, diagnosis, and management of major neurodegenerative disorders. The platform combines cMRI (fully automated brain MRI quantification with validated imaging biomarkers) and cDSI (AI-supported differential diagnosis using patented disease state fingerprint technology that compares a patient's data to 2,000+ confirmed neurodegenerative disease cases), along with cPET and cDAT modules for nuclear medicine imaging quantification. The solution is sold to hospitals, memory clinics, radiology departments, and medical imaging centers to support neurologists, radiologists, and geriatricians in making earlier and more confident diagnostic and disease-progression decisions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Compares patient data to 2,000+ patients with confirmed neurodegenerative disease for accurate differential diagnosis
Product overview1 text field

Combinostics offers a complete AI solution for the early detection, diagnosis, and management of major neurological disorders through its cloud-based cNeuro platform. The platform consists of two main integrated applications: cMRI (fully automated MRI quantification) and cDSI (AI-supported differential diagnosis and disease progression prediction). cMRI provides fully automated brain MRI analysis while cDSI combines this imaging data with other patient data including biomarkers, clinical and neuropsychological tests, and demographic data using AI methods and patented disease state fingerprint technology. The platform supports Neurology, Nuclear Medicine, and Radiology workflows, enabling radiologists and clinicians to communicate more effectively across different organizations. Additional modules include cPET for PET image quantification and cDAT for DAT SPECT imaging analysis.

Product and service6 records
1cNeuro Platform
CategoryCloud AI Diagnostic Platform
Description

Cloud-based AI platform that connects the cMRI and cDSI applications with multiple external data sources for comprehensive patient management in neurological disorders, sold to hospitals, memory clinics, and medical imaging centers.

2cNeuro cMRI
CategoryMedical Imaging Analysis Software
Description

Fully automated MRI quantification application that provides biomarker detection and reporting, evaluates brain atrophy and structural changes, quantifies white matter abnormalities, and compares results to reference data; usable as a standalone application for radiology departments and imaging centers.

3cNeuro cDSI (Clinical Decision Support)
CategoryClinical Decision Support Software
Description

AI-supported differential diagnosis and prediction system for neurodegenerative diseases that combines imaging data with clinical data, biomarkers, neuropsychological tests, and demographic data using patented disease state fingerprint technology for neurologists and memory clinics.

4cNeuro cPET
CategoryMedical Imaging Analysis Software
Description

Application for quantification and analysis of PET images used in nuclear medicine departments for neurological disorder assessment.

5cNeuro cDAT
CategoryMedical Imaging Analysis Software
Description

Application for quantification of DAT SPECT images for dopamine transporter imaging in neurodegenerative disease diagnosis, released in Europe in December 2023.

6Dementia Differential Analysis Report
CategoryClinical Decision Support Report
Description

Report generated from MRI data using cDSI's proprietary machine learning method that measures similarity of disease-specific imaging biomarker values against 2,000+ confirmed neurodegenerative disease patients, supporting diagnoses including Alzheimer's disease, frontotemporal dementia, vascular dementia, and cognitively normal.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-28
Description

Acquisition by SyntheticMR AB in January 2025 for EUR 4.3 million to integrate Combinostics' cNeuro platform and strengthen SyntheticMR's AI-based neuroimaging capabilities in the European market.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic technology partnership for integration of cNeuro AI diagnostic platform with GE Healthcare medical imaging systems, enabling combined imaging and AI analysis solutions for healthcare providers.

Strategic tierCoreTypeTechnology or Integration
Description

Technology partnership integrating cNeuro platform with Siemens Healthineers imaging equipment and software solutions for comprehensive neuroimaging diagnostics.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership integrating cNeuro AI diagnostics with Sectra medical imaging IT solutions for enhanced radiology workflow and diagnostic capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Aidoc is a leading clinical AI platform spanning multiple imaging modalities including neurological AI for stroke triage; broader portfolio than Combinostics but overlapping in hospital neuroimaging AI adoption.

TypeEmerging player
Description

Quibim offers AI-based quantitative imaging biomarkers for brain MRI and other organs, with similar disease-state fingerprinting approaches to neurodegenerative disease diagnosis.

TypeBroad incumbent
Description

Viz.ai's hyperacute stroke workflow AI overlaps in the neurology imaging AI category and competes for the same hospital informatics budgets, though focused on acute rather than neurodegenerative use cases.

TypeDirect peer
Description

icometrix provides AI-powered MRI brain quantification solutions (icobrain) for multiple sclerosis and dementia; it is the most directly comparable neuroimaging AI platform to Combinostics' cNeuro cMRI.

TypeBroad incumbent
Description

Qure.ai offers FDA-cleared AI for head CT/MRI including neurodegeneration-adjacent use cases; competes for similar radiology AI procurement opportunities globally.

TypeBroad incumbent
Description

RapidAI focuses on neuroimaging AI for stroke and other conditions, sharing the hospital neuroimaging AI install footprint with Combinostics even though its modality mix differs.

TypeEmerging player
Description

Cortechs.ai develops NeuroQuant and similar quantitative brain MRI tools, historically the incumbent in the brain volumetry space where Combinostics' cMRI now competes.

TypeEmerging player
Description

Pixyl provides AI-driven brain MRI biomarkers for MS and neurodegeneration, a smaller direct competitor targeting the same neuroimaging AI budget at hospitals.

TypeEmerging player
Description

Annalise.ai provides comprehensive radiology AI including brain CT/MRI analysis, competing for radiology department AI budgets and broader diagnostic imaging workflows where Combinostics is sold.

TypeDirect peer
Description

Parent company of Combinostics since January 2025, offering SyMRI quantitative MRI software; combines product overlap and now corporate integration with Combinostics' cNeuro platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Combinostics

Medical Imaging AI Softwarecombinostics.com

Combinostics is a Finland-based medical technology company that provides AI-powered neuroimaging diagnostic support for neurodegenerative diseases via its cloud-based cNeuro platform, sold to hospitals, memory clinics, and radiology/nuclear-medicine departments across Europe and the US.

What Combinostics does

Combinostics Oy (founded 2014, headquartered in Tampere, Finland, with a US subsidiary, Combinostics US Inc., in Boston) develops AI-driven neuroimaging diagnostic software for neurodegenerative diseases. Its core offering is the cloud-based cNeuro platform, which combines two integrated applications: cMRI, which performs fully automated quantification of brain MRI scans (detecting atrophy, white-matter abnormalities, and benchmarking against reference data); and cDSI (Clinical Decision Support), which uses a patented disease-state-fingerprint machine-learning method to compare a patient's imaging biomarkers against more than 2,000 confirmed cases of Alzheimer's disease, frontotemporal dementia, vascular dementia, and cognitively normal patients to support differential diagnosis and predict disease progression. The platform also includes cPET for PET image quantification and cDAT for DAT SPECT quantification (released in Europe in December 2023). Marketing materials position Combinostics as the only vendor offering a complete AI solution spanning the full patient-care pathway for major neurological disorders, integrating imaging biomarkers with clinical, neuropsychological, and demographic data.

The company sells cNeuro primarily through enterprise field sales to memory clinics, neurology departments, radiology departments, and nuclear-medicine units within hospitals and healthcare systems (named reference customers include Karolinska University Hospital, CIMF Fribourg, and Unilabs Sweden), supplemented by strategic technology integrations with GE Healthcare, Siemens Healthineers, and Sectra that distribute the platform through major imaging-vendor installed bases. Revenue is generated via cloud-based recurring subscription, with separate US and EU regional cloud portals for data-hosting compliance. The company remained privately held and small-scale (11-50 employees) until January 2, 2025, when it was acquired by SyntheticMR AB for EUR 4.3 million (~$5.03 million), mostly in cash with the remainder via promissory note and convertibles, and now operates as a wholly-owned subsidiary within SyntheticMR's AI-based neuroimaging portfolio.

Combinostics participates in industry conferences (notably RSNA), maintains thought-leadership content on neuroimaging and AI, and operates a free-trial and demo-request funnel. The company's addressable market — AI-assisted brain diagnostics — is projected to grow from $1.74 billion in 2024 to $5.46 billion in 2029, with the broader brain AI-assisted diagnosis market forecasted at $6.84 billion by 2030 at a 25.5% CAGR. Independent revenue figures are not publicly disclosed; the modest acquisition valuation relative to a high-growth end market implies sub-$5M standalone ARR on the eve of the SyntheticMR transaction.

Combinostics firmographics

Firmographics
Name
Combinostics
Legal name
Combinostics Oy
Website
https://combinostics.com
Company type
Private
Founded year
2014
Operating status
Acquired
Headcount range
1–10 employees
Short description
Combinostics is a Finland-based medical technology company that provides AI-powered neuroimaging diagnostic support for neurodegenerative diseases via its cloud-based cNeuro platform, sold to hospitals, memory clinics, and radiology/nuclear-medicine departments across Europe and the US.
Ownership category
akta.pro rank

Combinostics industry classification

Industry
Product category
Medical Imaging AI Software
NAICS
Computer Systems Design and Related Services (54151), Other Computer Related Services (541519)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Neuroimaging software
  • AI diagnostic platform
  • Brain MRI quantification
  • Neurodegenerative disease diagnostics
  • Clinical decision support

Where Combinostics is headquartered

Location

Headquarters

HQ city
Tampere
HQ country
Finland
HQ region
Europe

Offices2 records

Markets served

Combinostics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. cNeuro Platform Subscription: Cloud-based AI diagnostic platform offered as subscription service to healthcare providers, hospitals, and medical imaging centers for neuroimaging analysis and neurodegenerative disease diagnosis support.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Combinostics product offering

Product offering

Core offering

Combinostics develops and sells the cloud-based cNeuro platform, an AI-driven diagnostic suite for the early detection, diagnosis, and management of major neurodegenerative disorders. The platform combines cMRI (fully automated brain MRI quantification with validated imaging biomarkers) and cDSI (AI-supported differential diagnosis using patented disease state fingerprint technology that compares a patient's data to 2,000+ confirmed neurodegenerative disease cases), along with cPET and cDAT modules for nuclear medicine imaging quantification. The solution is sold to hospitals, memory clinics, radiology departments, and medical imaging centers to support neurologists, radiologists, and geriatricians in making earlier and more confident diagnostic and disease-progression decisions.

Product overview

Combinostics offers a complete AI solution for the early detection, diagnosis, and management of major neurological disorders through its cloud-based cNeuro platform. The platform consists of two main integrated applications: cMRI (fully automated MRI quantification) and cDSI (AI-supported differential diagnosis and disease progression prediction). cMRI provides fully automated brain MRI analysis while cDSI combines this imaging data with other patient data including biomarkers, clinical and neuropsychological tests, and demographic data using AI methods and patented disease state fingerprint technology. The platform supports Neurology, Nuclear Medicine, and Radiology workflows, enabling radiologists and clinicians to communicate more effectively across different organizations. Additional modules include cPET for PET image quantification and cDAT for DAT SPECT imaging analysis.

Differentiator

Problem solved

Functional benefit

Brands

  • cNeuro: A complete cloud-based AI solution for early detection, diagnosis, and management of major neurological disorders. Combines cMRI and cDSI applications.
  • cMRI
  • cDSI
  • cPET
  • cDAT

Products and services

  • cNeuro Platform Cloud-based AI platform that connects the cMRI and cDSI applications with multiple external data sources for comprehensive patient management in neurological disorders, sold to hospitals, memory clinics, and medical imaging centers.
  • cNeuro cMRI Fully automated MRI quantification application that provides biomarker detection and reporting, evaluates brain atrophy and structural changes, quantifies white matter abnormalities, and compares results to reference data; usable as a standalone application for radiology departments and imaging centers.
  • cNeuro cDSI (Clinical Decision Support) AI-supported differential diagnosis and prediction system for neurodegenerative diseases that combines imaging data with clinical data, biomarkers, neuropsychological tests, and demographic data using patented disease state fingerprint technology for neurologists and memory clinics.
  • cNeuro cPET Application for quantification and analysis of PET images used in nuclear medicine departments for neurological disorder assessment.
  • cNeuro cDAT Application for quantification of DAT SPECT images for dopamine transporter imaging in neurodegenerative disease diagnosis, released in Europe in December 2023.
  • Dementia Differential Analysis Report Report generated from MRI data using cDSI's proprietary machine learning method that measures similarity of disease-specific imaging biomarker values against 2,000+ confirmed neurodegenerative disease patients, supporting diagnoses including Alzheimer's disease, frontotemporal dementia, vascular dementia, and cognitively normal.

Quantifiable outcome

  • Compares patient data to 2,000+ patients with confirmed neurodegenerative disease for accurate differential diagnosis

Companies that use Combinostics

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Combinostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Combinostics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • SyntheticMR ABcoreStrategic or Co-development Partner · 28 November 2024Acquisition by SyntheticMR AB in January 2025 for EUR 4.3 million to integrate Combinostics' cNeuro platform and strengthen SyntheticMR's AI-based neuroimaging capabilities in the European market.
  • GE HealthcarecoreTechnology or IntegrationStrategic technology partnership for integration of cNeuro AI diagnostic platform with GE Healthcare medical imaging systems, enabling combined imaging and AI analysis solutions for healthcare providers.
  • Siemens HealthineerscoreTechnology or IntegrationTechnology partnership integrating cNeuro platform with Siemens Healthineers imaging equipment and software solutions for comprehensive neuroimaging diagnostics.
  • SectracoreTechnology or IntegrationPartnership integrating cNeuro AI diagnostics with Sectra medical imaging IT solutions for enhanced radiology workflow and diagnostic capabilities.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Combinostics competitors and assessment

Company assessment

Broad incumbents

  • Aidoc: Aidoc is a leading clinical AI platform spanning multiple imaging modalities including neurological AI for stroke triage; broader portfolio than Combinostics but overlapping in hospital neuroimaging AI adoption.
  • Viz.ai: Viz.ai's hyperacute stroke workflow AI overlaps in the neurology imaging AI category and competes for the same hospital informatics budgets, though focused on acute rather than neurodegenerative use cases.
  • Qure.ai: Qure.ai offers FDA-cleared AI for head CT/MRI including neurodegeneration-adjacent use cases; competes for similar radiology AI procurement opportunities globally.
  • RapidAI: RapidAI focuses on neuroimaging AI for stroke and other conditions, sharing the hospital neuroimaging AI install footprint with Combinostics even though its modality mix differs.

Emerging players

  • Quibim: Quibim offers AI-based quantitative imaging biomarkers for brain MRI and other organs, with similar disease-state fingerprinting approaches to neurodegenerative disease diagnosis.
  • Cortechs.ai: Cortechs.ai develops NeuroQuant and similar quantitative brain MRI tools, historically the incumbent in the brain volumetry space where Combinostics' cMRI now competes.
  • Pixyl: Pixyl provides AI-driven brain MRI biomarkers for MS and neurodegeneration, a smaller direct competitor targeting the same neuroimaging AI budget at hospitals.
  • Annalise.ai: Annalise.ai provides comprehensive radiology AI including brain CT/MRI analysis, competing for radiology department AI budgets and broader diagnostic imaging workflows where Combinostics is sold.

Direct peers

  • icometrix: icometrix provides AI-powered MRI brain quantification solutions (icobrain) for multiple sclerosis and dementia; it is the most directly comparable neuroimaging AI platform to Combinostics' cNeuro cMRI.
  • SyntheticMR: Parent company of Combinostics since January 2025, offering SyMRI quantitative MRI software; combines product overlap and now corporate integration with Combinostics' cNeuro platform.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Combinostics social profiles

Digital presence

Combinostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Combinostics leadership team

Management profile

Number of profiles

Profiles3 records

Combinostics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Combinostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Combinostics

What does Combinostics do?

Combinostics develops and sells the cloud-based cNeuro platform, an AI-driven diagnostic suite for the early detection, diagnosis, and management of major neurodegenerative disorders. The platform combines cMRI (fully automated brain MRI quantification with validated imaging biomarkers) and cDSI (AI-supported differential diagnosis using patented disease state fingerprint technology that compares a patient's data to 2,000+ confirmed neurodegenerative disease cases), along with cPET and cDAT modules for nuclear medicine imaging quantification. The solution is sold to hospitals, memory clinics, radiology departments, and medical imaging centers to support neurologists, radiologists, and geriatricians in making earlier and more confident diagnostic and disease-progression decisions.

Is Combinostics a public or private company?

Combinostics is a private company. It is classified as corporate owned and is currently acquired.

When was Combinostics founded?

Combinostics was founded in 2014. It employs 1 to 10 people.

Where is Combinostics based?

Combinostics is headquartered in Tampere, Finland, in the Europe region.

How does Combinostics make money?

One revenue line is on record: cNeuro Platform Subscription.

Who are Combinostics's main competitors?

Broad incumbents on record are Aidoc, Viz.ai, Qure.ai and RapidAI. Emerging players are Quibim, Cortechs.ai, Pixyl and Annalise.ai. Direct peers are icometrix and SyntheticMR.

Does Combinostics have an API?

No public API is recorded for Combinostics.

What industry is Combinostics in?

Combinostics's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 54151 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comInterim report April – June 2026SyntheticMR reported Q2 2026 net sales of 14.0 MSEK, up 13%, with an operating loss of -6.5 MSEK and net loss of -6.1 MSEK. cMRI ARIA received regulatory approval in the UK and Switzerland, and the company is awaiting FDA feedback on its US review. The company aims to achieve profitability through increased sales and cost control.EIN Presswire3DR Labs and Combinostics Streamline Neuroradiology Workflows with AI-Powered Brain Quantification3DR Labs and Combinostics announced a collaboration to integrate Combinostics' FDA-cleared cMRI, cDSI, cPET, and cDAT software into 3DR's AI Labs platform. The integration provides automated, normative-based brain quantification for MR, PET, and SPECT imaging, supporting diagnosis and monitoring of neurodegenerative diseases like dementia and MS. The algorithms are validated against large normative datasets.openPR.comEmerging Sub-Segments Transforming the Brain Artificial Intelligence (AI)-Assisted Diagnosis Solution MarketThe brain AI-assisted diagnosis solution market is projected to grow to $6.84 billion by 2030, with a compound annual growth rate of 25.5%, driven by increasing demand for early neurological diagnosis and greater adoption of AI diagnostic tools in clinical settings. In January 2025, Swedish healthcare firm SyntheticMR AB acquired Finland-based Combinostics Oy for $5.03 million (€4.3 million) to integrate Combinostics' cNeuro platform and strengthen SyntheticMR's AI-based neuroimaging capabilities in the European market.news.cision.comYear-End report January – December 2025SyntheticMR AB reported its year-end financial results for 2025, with net sales increasing by 2% to SEK 57 million and an improvement in operating profit to SEK –49.3 million. The company achieved regulatory approvals for its products in India, Europe, Japan, and South Korea, and completed an acquisition of Combinostics. Despite financial challenges, the company outlined its strategic focus on commercial execution and long-term growth, especially in the U.S. and Asian markets.GlobeNewswireBrain Artificial Intelligence Assisted Diagnosis Solution Report 2025: Market to Hit $5.46 Billion by 2029 as Neuroimaging and Preventive Digital Health Accelerate Adoption - Forecast to 2034Research and Markets released a report forecasting the global brain AI-assisted diagnosis solution market to grow from $2.19 billion in 2025 to $5.46 billion by 2029, driven by rising neurological disorders and healthcare digitization. Key industry developments include BrainScope Company Inc.'s launch of a new deep learning platform for EEG analysis and SyntheticMR AB's acquisition of Combinostics Oy to expand its neuroimaging portfolio.news.cision.comSyntheticMR completes the acquisition of Combinostics OySyntheticMR completed its acquisition of Finnish Combinostics on January 2, 2025, paying EUR 4.3 million total. Approximately EUR 3.93 million was paid in cash, with the remainder settled via a promissory note offset against convertibles. The deal aims to strengthen SyntheticMR's market position by combining the two companies' technology and expertise.CombinosticsCombinostics and SyntheticMR to join forcesSyntheticMR agreed to acquire all shares in Combinostics, subject to shareholder approval. The deal combines SyntheticMR's MRI software with Combinostics' segmentation algorithms to serve neurodegenerative disease markets. SyntheticMR expects to expand its customer offering in 2025.news.cision.comSyntheticMR signs agreement to acquire Finnish Combinostics OySyntheticMR signed an agreement to acquire Finnish Combinostics, a medical technology and software company, for EUR 4.3 million. The deal includes approximately EUR 3.93 million in cash and EUR 0.37 million in convertible notes, with closing expected around January 2025.GlobeNewswireArterys Partners With Combinostics to Accelerate Accurate and Consistent Evaluations of Patients With Neurodegenerative Disease and Multiple SclerosisArterys announced a partnership with Combinostics to integrate the cNeuro AI imaging suite on its MICA platform, covering neuroradiology applications. The fully automated cMRI algorithms will be available to existing customers in coming weeks, supporting evaluations for neurological disorders like dementia and multiple sclerosis.FinSMEsCombinostics Raises €3.9M in Series A FundingCombinostics, a Tampere-based health tech firm, closed a €3.9M Series A round led by Industrifonden and NordicNinja VC. The funds will scale its cNeuro platform for early Alzheimer's diagnosis to the US and Asia. The company aims to support healthcare professionals in diagnosing neurodegenerative diseases.